Table 1.
Case reports of taxane chemotherapy related myelogenous leukemias.
| Author | Year | Age | Primary tumor | Docetaxel | Paclitaxel (total dose in mg) | Carboplatin (total dose in mg) | Karyotype | Latency of leukemia (period from initial treatment to onset of AML) | MDS | AML | Prognostic: time from Dx of AML to death |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ishikawa et al. [8] | 2014 | 65 | Ovarian cancer | 1968 | 6480 |
45,XX,der(6)t(6:17)(p23;q21)inv(6)(p23q13),17, add(19)(p13)[4]/44,sl-5[10]/46,XX[5] |
3 years 10 months | MDS-RCMD | — | 15 m | |
|
| |||||||||||
| Vanajakshi et al. [9] | 2014 | 69 | Ovarian cancer | 1200 | 2700 | 53XX; trisomies 8, 12, 16, 18, 19, and +2mar JAK2V617F; 5q31 and 7q31 deletions | 33 months | MDS-U | M4 | 1 m of AML | |
|
| |||||||||||
| See et al. [10] | 2006 | 54 | Ovarian cancer | 1710 | 6820 | Abnormal karyotype with multiple complex abnormalities, including 45XX t(1,5)(q25;q35),del(4) (q21q26),ins(7)(p15;?),del(12)(p12),213,217,217, add(19)(p13.3), add(22)(q13),12mar in 11 metaphases and 43–45,XX,t(1;5) (q25;q35),del(4)(q21q26),ins(7)(p15;?) del(12)(p12),213,217,217,add(19)(p13.3), add(22)(q13),1224mar in 8 metaphases were identified at diagnosis of erythroleukemia |
36 months | — | M6 | 10 m after dx of AML | |
|
| |||||||||||
| Yeasmin et al. [11] | 2008 | 73 | Ovarian cancer | 2085 | 1910 | 46,XX,der(5,19)(p10:q10),−6,del(7)(q?), add(12)(p11.2),−13,−17,+19 |
24 months | MDS-RAEB | M7 | 2 m | |
|
| |||||||||||
| Kim et al. [12] | 2006 | 64 | NSCLC | 525 | 1123 | NR | 27 months | MDS-CMML | 9 m | ||
|
| |||||||||||
| Gupta et al. [13] | 2014 | 64 | Breast cancer | (Dose not specified) | 46,XX,t(8;16)(p11.2;p13.3),der(22)t(1;22)(q21;q13) | 2 years | M4 | 1 m | |||
|
| |||||||||||
| Melichar et al. [14] | 2012 | 54 | Ovarian and breast cancer | (Dose not specified) | Cisplatin equivalents 3798 mg | NR | 5 years | MDS-RAEB | — | 3 m | |
|
| |||||||||||
| Melichar et al. [14] | 2012 | 66 | Ovarian cancer | 31 cycles × 175 mg/m2 | Cisplatin equivalents 4050 mg | NR | 43 months | Unclassified | 1 m | ||
|
| |||||||||||
| Christodoulou et al. [15] | 2004 | 21 | Mixed germ cell tumor (seminoma) | 1000 | 47,XY,i(5)(p10),del(12)(p11),+i(12)(p10) [18] | 10 months | MDS (RARS) | — | Survived | ||
|
| |||||||||||
| Seymour et al. [16] | 1999 | 59 | Ovarian cancer | 1800 | 3600 | NR | 22 months | M4 | Survived | ||
|
| |||||||||||
| Seymour et al. [16] | 1999 | 54-55 | Neuroendocrine cancer of ovary | 450 | 750 | NR | 8 months | M4 | 10 weeks | ||
|
| |||||||||||
| Griesinger et al. [17] | 2004 | 74 | NSCLC stage IIIB | 4 cycles × 100 mg/m2 | 4800 | NR | 40 months | MDS-RA | M2 | 40 m | |
|
| |||||||||||
| Current | 2014 | 63 | Endometrial cancer | 1511 | 4312 | 45,XX,add(3)(p13),del(3)(q23q25),−5,add(5)(q13), add(7)(q11.2),der(17)t(5,17)(q15;q25) |
7.5 months | MDS-RAEB | M4 | 2 weeks | |